Emerging strategies, including bevacizumab for symptom control and MEK inhibitors for NF–1-associated gliomas, show promise, while immunotherapy and CAR T-cell therapy hold potential to transform the therapeutic landscape. This evidence concerns the gene MAP2K7 and central nervous system cancer.